These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21514066)

  • 21. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
    Hoffman KE; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin MJ; Ross R; D'Amico AV
    Cancer; 2010 Jun; 116(11):2590-5. PubMed ID: 20310055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):147-52. PubMed ID: 19744800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
    Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
    JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.
    Wo JY; Chen MH; Nguyen PL; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
    J Clin Oncol; 2009 Dec; 27(35):6000-5. PubMed ID: 19858385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research.
    Johnstone PA; Kane CJ; Sun L; Wu H; Moul JW; McLeod DG; Martin DD; Kusuda L; Lance R; Douglas R; Donahue T; Beat MG; Foley J; Baldwin D; Soderdahl D; Do J; Amling CL
    Radiology; 2002 Nov; 225(2):420-6. PubMed ID: 12409575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
    Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.
    Shen X; Keith SW; Mishra MV; Dicker AP; Showalter TN
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1154-9. PubMed ID: 22270175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.
    Kestin LL; Goldstein NS; Vicini FA; Martinez AA
    J Urol; 2002 Nov; 168(5):1994-9. PubMed ID: 12394693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort.
    Du XL; Fang S; Coker AL; Sanderson M; Aragaki C; Cormier JN; Xing Y; Gor BJ; Chan W
    Cancer; 2006 Mar; 106(6):1276-85. PubMed ID: 16475208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary causes of death after permanent prostate brachytherapy.
    Bittner N; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Brammer SG; Moyad M
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):433-40. PubMed ID: 18448268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comorbidity as a predictor of overall survival in prostate cancer patients treated with external beam radiotherapy combined with HDR brachytherapy boosts.
    Hjälm-Eriksson M; Ullén A; Johansson H; Levitt S; Nilsson S; Kälkner KM
    Acta Oncol; 2017 Jan; 56(1):21-26. PubMed ID: 27882806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Curative brachytherapy for prostate cancer in African-Caribbean patients: A retrospective analysis of 370 consecutive cases.
    Atallah V; Leduc N; Creoff M; Sargos P; Taouil T; Escarmant P; Vinh-Hung V
    Brachytherapy; 2017; 16(2):342-347. PubMed ID: 28024937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of a racially and ethnically diverse population of men with localized prostate cancer who did not undergo initial active treatment.
    Slezak JM; Van Den Eeden SK; Cannavale KL; Chien GW; Jacobsen SJ; Chao CR
    Cancer Med; 2020 Nov; 9(22):8530-8539. PubMed ID: 32965775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
    Underwood W; Jackson J; Wei JT; Dunn R; Baker E; Demonner S; Wood DP
    Cancer; 2005 Feb; 103(3):538-45. PubMed ID: 15612083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of brachytherapy for prostate cancer in African Americans compared with Caucasians.
    Barrett WL; Kassing WM; Shirazi R
    Brachytherapy; 2004; 3(1):30-3. PubMed ID: 15110311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.
    Tilki D; Chen MH; Wu J; Huland H; Graefen M; Braccioforte M; Moran BJ; D'Amico AV
    JAMA Oncol; 2019 Feb; 5(2):213-220. PubMed ID: 30452521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.